Ok, I looked into this because sometimes claims that "China invents Y" can be somewhat exaggerated. But this is real, and completely insane. This technology called "Bone 02" (inspired by the well-known "502 glue" in China) has been developed for the past 9 years by a team of orthopedic surgeons in Zhejiang province. The team leads are Professor Fan Shunwu (范顺武, Director of the Orthopedics Department at Zhejiang University) and Lin Xianfeng (researchgate.net/profile/Xia…). It's inspired by oysters because the researchers noticed their extraordinary ability to firmly attach themselves in harsh underwater environment by secreting a special adhesive known as bio-cement, which creates a strong chemical interaction with surfaces and hardens quickly. The properties of the glue are almost miraculous (sources: news.cn/20250910/1df9380a9ed… and news.ifeng.com/c/8mVMq4PBdmJ): - Nearly instant adhesion in blood-soaked wet physiological environments (it just takes 2-3 minutes) - Extremely strong adhesive properties (bonding tensile force of over 400 pounds - over 181 kg) - Complete biodegradability that naturally absorbs after about 6 months as the bone heals (no need for secondary surgery previously required in conventional treatments) - Vast reduction of infection risks related to the traditional metal plates and screws normally needed for bone surgery - Minimally invasive and rapid surgery since you just need a small opening large enough to apply the glue (as opposed to a complex surgery attaching metal fixations) This glue could be especially useful for fractures with small bone fragments which are very difficult to fix with metal plates and screws. The glue has already undergone a proper "prospective, multicenter, blinded, randomized, parallel-controlled, non-inferiority clinical trial" with over 150 patients (c.m.163.com/news/a/K95S9C0M0…). They've announced positive results - the glue "achieved seamless bonding of all fracture fragments" - and will soon publish the peer-reviewed paper in an orthopedics journal detailing full trial data. They've launched a company for the product called 源囊生物 (Yuannang Bio) which just raised 2 weeks ago RMB100 million in Series A financing (bydrug.pharmcube.com/news/de…).